title: [Adduction spastic dysphonia: clinical and treatment].
abstract: Adduction spastic dystonia (SD) is currently considered a focal dystonia involving laryngeal muscles. SD is one of the most poorly known focal dystonias. We reviewed our experience with twentynine patients with adduction SD and compared the clinical and epidemiologic variables with the other focal dystonias studied at our institution in the last five years (132 patients). Mean age of patients (47.2 +/- 13 years), sex, clinical course in years (5.7 +/- 5) and presence of circadian fluctuations did not differ significantly from those observed in patients with other focal dystonias. Likewise, there were no significant differences regarding the presence of a family history of dystonia, essential tremor, or stuttering. Our results confirm the similarity of the clinical and epidemiologic data of SD with the other focal dystonias. All patients with SD were treated with a local injection of botulinum toxin. A total of 108 treatments were performed, 41 with a visually guided transoral technique and 67 with a percutaneous technique. The transoral technique was effective in all cases (41/41) but not all treatments with the percutaneous technique were effective (53/67). Three patients required the shift to the transoral procedure to achieve enough symptomatic alleviation.
authors.affiliation: Servicio de Neurología, Fundación Jiménez Díaz, Madrid.
authors.forename: P J
authors.initials: PJ
authors.lastname: García Ruiz
authors.forename: M
authors.initials: M
authors.lastname: Sánchez del Río
authors.forename: C
authors.initials: C
authors.lastname: Cenjor Español
authors.forename: J
authors.initials: J
authors.lastname: Sanabria Brassart
authors.forename: V
authors.initials: V
authors.lastname: Sánchez Bernardos
authors.forename: R
authors.initials: R
authors.lastname: Astarloa Gómez
authors.forename: J
authors.initials: J
authors.lastname: García de Yébenes
mesh_terms: D000328:Adult; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use; D004421:Dystonia / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014832:Voice Disorders / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy
chemical_list: D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins
vernacular_title: Disfonía espástica de aducción: clínica y tratamiento.